Definitive Agreement to Acquire Exelead will Strengthen Merck’s CDMO Offering for mRNA
Merck has signed a definitive agreement to acquire Exelead, a biopharmaceutical contract development and manufacturing organization (CDMO), for approximately USD 780 million in cash. Targeted […]